Natco Pharma Files FY26 Annual Report, Schedules 43rd AGM
Natco Pharma Ltd has filed its Annual Report for the Financial Year 2025-26, coinciding with the announcement of its 43rd Annual General Meeting (AGM) scheduled for September 30, 2026. The report highlights the company's strategic focus on expanding access to specialty medicines globally. Key initiatives include strengthening its formulations export business and entering the South African market through a 49% stake acquisition in Adcock Ingram Holdings Proprietary Limited. The company also celebrated significant product launches, including the first affordable generic Semaglutide injection (vials) and the first generic Risdiplam injection in India. Natco emphasizes its commitment to operational excellence, global footprint expansion, and creating sustainable value, driven by scientific talent and manufacturing capabilities.
Key Highlights
- Filed FY25-26 Annual Report and announced 43rd AGM for Sep 30, 2026.
- Acquired 49% stake in South Africa's Adcock Ingram Holdings.
- Launched first affordable generic Semaglutide injection (vials).
- Launched first generic Risdiplam injection in India.
- Focus on expanding global presence and specialty medicine access.
Price Impact
More from NATCOPHARM